)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
BioVie
BioVie (BIVI) investor relations material
BioVie Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary18 Jun, 2026
Company overview and business model
Clinical-stage company focused on developing innovative drug therapies for neurological, neurodegenerative disorders, and advanced liver disease.
Lead asset bezisterim (NE3107) targets inflammation-driven insulin resistance, with potential applications in Alzheimer's, Parkinson's, and long COVID.
Pipeline includes BIV201 for liver cirrhosis and ascites, with FDA Fast Track and Orphan Drug designations.
Financial performance and metrics
As of June 8, 2026, aggregate market value of outstanding common stock held by non-affiliates was approximately $12.5 million, based on 7,292,401 shares at $1.72 per share.
No dividends have been declared or paid; all earnings are retained for business development and growth.
Use of proceeds and capital allocation
Net proceeds from securities sales will be used for working capital, capital expenditures, R&D, and potential acquisitions.
Specific allocation and timing will depend on funding requirements and capital availability.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from BioVie
- Imminent clinical data for Parkinson's and Long COVID could unlock major market opportunities.BIVI
Investor update2 Jun 2026 - Bezisterim and BIV201 show promising efficacy in neurodegenerative and liver disease trials.BIVICorporate presentation2 Jun 2026
- Bezisterim targets neuroinflammation and metabolic dysregulation to address Parkinson's progression.BIVIKOL event14 May 2026
- Net loss widened to $5.3M for the quarter as R&D spending rose, with cash at $13.1M.BIVIQ3 202611 May 2026
- Lead therapies show strong efficacy in neurodegeneration and ascites, with high commercial potential.BIVICorporate presentation23 Apr 2026
- Imminent clinical data for Parkinson's and long COVID could unlock major market opportunities.BIVIBiotech Resurgence: Platforms and Pipelines of Today's Innovators16 Apr 2026
- Phase II data for Parkinson's and long COVID expected in 2024; BIV201 phase III planning underway.BIVIStatus update4 Mar 2026
- Net loss narrowed, cash bolstered by $10.5M raise, but going concern risks persist.BIVIQ2 20266 Feb 2026
- Directors elected, auditor ratified, and equity plan amendment approved by strong majority.BIVIAGM 20253 Feb 2026
Next BioVie earnings date
Q4 202614 Aug, 2026
BioVie
Next BioVie earnings date
Q4 202614 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage